The page is the record's research on the issuer — no analyst, no rating, no view. # Aligos Therapeutics, Inc. (NASDAQ: ALGS) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Aligos Therapeutics, Inc., listed on NASDAQ under ticker ALGS, ISIN US01626L2043, LEI 549300UU2UJIKJYX0S67. Its security type is Corporate. Its segment is not on the record. Its sector is 2836 Biological Products, (No Diagnostic Substances), and its jurisdiction is United States — Delaware. Its listing status is listed, not halted. ## The disclosure read The record holds 35 filings across 18 filing days in the twelve months to 2026-11-08. The median gap between filing days is 8 days. The latest filing is dated 2026-11-06, a results filing, 2 days before the record date. The exchange median gap is 6.0 days across 4359 issuers, and the sector median gap is 5.5 days across 176 issuers. The exchange median is 52 filings and the sector median is 65.5 filings. The exchange median latency is 5.0 days and the sector median latency is 4.0 days. The issuer's 35 filings are below the exchange median of 52 and below the sector median of 65.5. By type, the window holds 11 directors' dealings, 9 regulatory filings, 8 results, 3 corporate news, 2 AGM/EGM and 2 director changes. ## Auditor The auditor of record is Ernst & Young LLP, located in San Francisco, California. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting, name change or segment move lines. Domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. Segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's investor-relations page. ## Open research No openly published research notes were found on the record. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The vintage is sealed. The issuer's sealed years are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 9 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin) - https://data.sec.gov/submissions/CIK0001799448.json (identity.jurisdiction) - https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei) - https://mcp.us-cm-kg.ai/events/NASDAQ/ALGS (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm (the auditor) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/ALGS (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/ALGS · public-record only · the same page signed and receipted: get_research at https://mcp.getissuer.ai/mcp